|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1997-3-31
|
|
pubmed:abstractText |
A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum- and paclitaxel-based regimens. Liposomal doxorubicin was selected as a result of its superior activity against ovarian cancer xenografts relative to free doxorubicin and activity in refractory ovarian cancer patients that was noted during the phase I study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BurnettAA,
pubmed-author:GarcinRR,
pubmed-author:GrecoF AFA,
pubmed-author:GroshenSS,
pubmed-author:HainsworthJ DJD,
pubmed-author:JeffersSS,
pubmed-author:LiangL JLJ,
pubmed-author:MillerPP,
pubmed-author:MorrowC PCP,
pubmed-author:MuderspachLL,
pubmed-author:MuggiaF MFM,
pubmed-author:ParadisoL JLJ,
pubmed-author:RomanLL,
pubmed-author:TasJJ,
pubmed-author:UzielyBB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
987-93
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9060537-Aged,
pubmed-meshheading:9060537-Antibiotics, Antineoplastic,
pubmed-meshheading:9060537-Antineoplastic Agents,
pubmed-meshheading:9060537-CA-125 Antigen,
pubmed-meshheading:9060537-Cisplatin,
pubmed-meshheading:9060537-Disease-Free Survival,
pubmed-meshheading:9060537-Doxorubicin,
pubmed-meshheading:9060537-Drug Administration Schedule,
pubmed-meshheading:9060537-Drug Carriers,
pubmed-meshheading:9060537-Drug Resistance, Neoplasm,
pubmed-meshheading:9060537-Female,
pubmed-meshheading:9060537-Humans,
pubmed-meshheading:9060537-Infusions, Intravenous,
pubmed-meshheading:9060537-Liposomes,
pubmed-meshheading:9060537-Middle Aged,
pubmed-meshheading:9060537-Neutropenia,
pubmed-meshheading:9060537-Ovarian Neoplasms,
pubmed-meshheading:9060537-Paclitaxel,
pubmed-meshheading:9060537-Ulcer
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
|
|
pubmed:affiliation |
Department of Radiology, University of Southern California-Norris Comprehensive Cancer Center, Los Angeles, USA. franco.muggia@ccmail.med.nyu.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
